Navigation Links
First-ever therapeutic offers hope for improving blood transfusions

Researchers from Case Western Reserve University School of Medicine have developed an unprecedented approach to restore nitric oxide (NO) to donated blood, a breakthrough that could dramatically reduce harmful effects from transfusions.

Jonathan Stamler, MD, and colleagues from Case Western Reserve School of Medicine and from Duke University Medical Center describe their findings in the June 24 issue of PNAS: Proceedings of the National Academy of Sciences of the United States of America. Stamler and his colleagues report that restoring blood levels of NO in animals prior to transfusion improved their tissue blood flow, oxygen delivery, and kidney function.

Patients in the U.S. receive approximately 15 million blood transfusions a year. The procedure is often used to replace blood lost through trauma, but also can supplement shortages in a patient's own ability to produce blood due to cancer and other diseases. Increasingly, medical research publications associate transfusions with harmful consequences including heart attacks, renal failure, and death. A compelling explanation put forward in the literature is that the quantity of NO declines rapidly after donation because it has a short lifespan. Normally, NO dilates blood vessels and allows red blood cells to access tissue and deliver oxygen.

In the blood, NO exists in a bioactive form called S-nitrosohemoglobin (SNO-Hb). The unique process Stamler and team developed to restore SNO-Hb so-called renitrosylation therapy could have significant benefits for millions of patients.

"Inasmuch of the world's supply of banked blood is deficient in SNO-Hb, efforts to restore its levels may hold great therapeutic promise," said Stamler, director, Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation, Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center, and director, Harrington Discovery Institute, UH Case Medical Center.

"One important aspect of our study is the insight that knowledge of banked blood's SNO-Hb status may be used to judge the efficacy of a transfusion," Stamler said.

This information would allow physicians to discriminate between blood donations that may cause harm versus those that will have restorative effects following transfusion.

The research team hypothesized that the loss of NO compromises the ability to dilate blood vessels and thereby deliver oxygen to tissues, which is critical for survival. Red blood cells lacking NO instead would plug small blood vessels and cause heart attacks and kidney failure. In contrast, restoration of NO would ensure oxygen delivery.

The study, funded by the National Heart Lung and Blood Institute (NHLBI), found that mice, rats and sheep transfused with untreated banked blood had decreased oxygen levels in skeletal muscle and other tissuesexactly the opposite of what would have been predicted. By contrast, in animals transfused with renitrosylated (NO repleted) red blood cells, tissue oxygenation improved. In addition, researchers applied the same treatment to anemic animals and found improved blood flow, tissue oxygenation, and kidney function.

Stamler explained that these results demonstrate that restoration of blood NO levels may be useful in treating and preventing a wide variety of conditions, including heart attacks and strokes, and kidney damage following surgery. The findings also may offer new promise for patients with sickle disease, malaria and other blood disorders. In addition, the data suggest that Stamler's therapeutic is a simple way to reverse the potential toxicity of regular blood transfusions.

The Food and Drug Administration considers a transfusion successful if 75 percent of the banked red blood cells are circulating in the body of the recipient 24 hours after administration.

"Based on our findings, the criteria might need to be revised to include measures of red blood cell functionnamely the ability of banked blood to deliver oxygen," Stamler added.

Motivated by these promising findings, Stamler has secured a grant from the NHLBI of the National Institutes of Health (NIH) to begin a clinical trial to evaluate the oxygen delivery function of banked blood. In addition, the team has applied for NHLBI funding of a Phase I clinical trial to study the use of renitrosylation in patient transfusions. If funded, the trial would be based at University Hospitals Case Medical Center and would enroll approximately 30 healthy volunteers.


Contact: Jessica Studeny
Case Western Reserve University

Related biology news :

1. First-ever 3-D stress map of developing embryonic heart sheds light on why defects form
2. Professor publishes on first-ever imaging of cells growing on spherical surfaces
3. China poised to accept first-ever non-animal test method for cosmetics
4. First-ever release of endangered burying beetles in Missouri
5. Scientists complete first-ever emperor penguin count from space
6. Drug development venture links translational research, business to launch new therapeutics
7. Autism discovery paves way for early blood test and therapeutic options
8. Salk scientists find potential therapeutic target for Cushings disease
9. Novel therapeutic approaches to cure chronic HBV infection
10. Intranasal neuropeptide Y may offer therapeutic potential for post-traumatic stress disorder
11. BUSM study reveals therapeutic targets to alter inflammation, type 2 diabetes
Post Your Comments:
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... Calif. , Nov. 17, 2015  Vigilant Solutions ... has joined its Board of Directors. ... Board after recently retiring from the partnership at TPG ... 107 companies with over $140 Billion in revenue.  He ... improvement across all the TPG companies, from 1997 to ...
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
(Date:11/24/2015)... , Nov. 24, 2015 According to two new ... 2005. This is something that many doctors, scientists, and public ... questions remains: with fewer PSA tests being done, will there ... Dr. David Samadi, "Despite the efforts made ... remains the second leading cancer cause of death in men, ...
(Date:11/23/2015)... ... 23, 2015 , ... Noblis, Inc., a leading provider of science, technology, and ... Geospatial Intelligence Agency (NGA), has joined the Noblis NSP team as President of the ... intelligence community and the private sector,” said L. Roger Mason, Jr., Ph.D. , ...
Breaking Biology Technology: